Thanks others @Marek78@Pledge for your thoughts. No thanks to @seahunt , although not unexpected as to date your contributions to this forum have primarily been trolling. I'd like to actually hear your considered responses, rather than just tropes about how dire things are.
Pledge, my thoughts are that indeed it is a speccy stock in a speccy industry, and although this is fairly new territory for me, I kind of imagine that in this space you have companies that are selling an idea that is yet to come to fruition (as is the case with AC8) but that those ideas are normally driven by a person/persons who developed that concept and want to see it to the end. What concerns me here is that those people who were involved in the original conception seem to have all left. I like the financial fundamentals, and some of the transitions made seem to make sense to capitalise on transition to pharmeutical company, but again why has everyone left?
As you say though, you're right I guess it doesn't matter who is there, either you believe what has been stated about the hard caps potential or not. It just seems a little scary that those involved in the company in the past that would have the best knowledge about their capacity have left. But yes, again, it's just a waiting game at the moment.
(20min delay)